August 2026
M	T	W	T	F	S	S
	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A

Wolfgang Miesbach /LinkedIn

Feb 23, 2026, 17:59

Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

“Resolution of chronic synovitis with Emicizumab?

Emicizumab continues to reshape our understanding of joint outcomes in severe Hemophilia A — transforming not only bleeding prevention, but also long‑term joint health.

At EAHAD2026, this poster by Matteo Di Minno, using HEAD‑US and HJHS in 52 adults on long‑term Emicizumab prophylaxis showed:

Significant improvement in hypertrophic synovium scores over ≥2 years
>50% of joints with hypertrophic synovium at baseline showed reduction or resolution
Very few de‑novo HS findings in previously unaffected joints, suggesting structural joint protection in routine practice

Interestingly, joints with pre‑existing degenerative changes improved the least – a strong reminder that timing of effective prophylaxis still matters.

It will be particularly interesting to see how these real‑world imaging data will align with the ongoing Phase IV Beyond ABR study (NCT05181618), which is exploring broader health and joint outcomes under Emicizumab.”

Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A